Project Grant R61HL154094

This $265,347 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development and initial validation of a point-of-care device to assess red blood cell sickling in sickle cell disease patients. The device, known as the Dynamic Sickling Assay (DSA), is designed to be a simple, standalone, and potentially CLIA-waived system with single-use disposable cartridges. The goal is for this system to...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2,095,816 Project Grant under CFDA 93.837 (Cardiovascular Diseases Research) to The DNA Medicine Institute, Inc. to develop a 5-minute point-of-care test that can rapidly measure anti-Factor Xa activity and hemoglobin levels. This device is intended to guide emergency management of patients on direct oral anticoagulants, enabling quicker delivery of life-saving interventions during bleeding events or strokes. The project will...

The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded a $487,350 Project Grant under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to Trustees of Tufts College (Tufts University) to develop paper-based microsampling devices that provide stable and metered samples of dried blood and plasma. The goal is to enable patient-centric microsampling approaches that allow blood to be self-collected via fingerstick...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $238,500 to the University of California, San Diego (UCSD) to develop a novel electrochemical lateral flow assay (ELFA) that can accurately diagnose active tuberculosis (TB) from a single drop of blood or urine. The primary objectives are to: 1) Determine the operating characteristics of the ELFA using contrived...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $295,895 to Ricovr Healthcare Inc. to develop a rapid, low-cost, point-of-care diagnostic platform for quantitatively measuring placental growth factor (PlGF) to predict and detect pre-eclampsia. The project aims to demonstrate the feasibility of this novel plasmonic fiber-optic...

This Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), provides $312,817 to Giner Inc., a small business R&D firm based in Massachusetts, to develop a point-of-care testing (POCT) instrument for highly sensitive and near-real-time measurement of oxytocin levels. The Phase I program will focus on improving and validating the company's novel electrochemical assay...

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Cooperative Agreement award for $997,142 aims to develop a rapid phenylalanine blood level monitor for patients with phenylketonuria (PKU), a lifelong genetic disorder. The product consists of a test strip and device that can provide frequent, accessible monitoring of phenylalanine levels from a finger prick to improve disease management and patient outcomes. The project focuses on optimizing the...

The National Center for Advancing Translational Sciences (NCATS), under CFDA 93.350, has awarded a $324,962 Project Grant to Tetmedical, Inc. to develop a technology for rapid, point-of-care and at-home testing of liver enzyme levels. The goal is to enable convenient and timely monitoring of drug-induced liver injury (DILI) and other sources of liver damage. The project aims to optimize tethered enzyme assays for detecting aspartate aminotransferase (AST) and alanine aminotransferase (ALT),...

The National Institute of Child Health and Human Development awarded a $383,192 Project Grant under the Child Health and Human Development Extramural Research program (CFDA 93.865) to Rhode Island Hospital, a division of Lifespan Corporation, to evaluate the use of a smartphone-based, non-invasive method for detecting anemia in young children in Western Kenya. This research seeks to develop and validate a mobile health (mHealth) screening tool that can accurately diagnose anemia, a common and...

This federal Project Grant award of $1,158,000 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to develop chemical modulators for the BCL11A protein, a validated target for treating sickle cell disease and beta-thalassemia. The goal is to leverage proximity-based protein depletion techniques, such as proteolysis targeting chimeras (PROTACs) and molecular glues, to effectively reduce BCL11A levels...